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	 Quality	by	Design	(QbD)	 for	 the	pharmaceutical	 industry	 includes	 the	design,	development
and	production	control	of	products	and	production	processes	from	the	beginning	to	the	end
of	 the	 product	 development	 phase	 for	 ensuring	 the	 consistent	 quality	 of	 a	 pharmaceutical
product.	 The	 QbD	 is	 a	 systematic	 scientific	 approach	 aimed	 at	 meeting	 the	 needs	 of	 the
patient	 in	 the	 desired	 and	 targeted	 quality	 and	 aiming	 to	 produce	 the	 same	 quality
pharmaceutical	product	in	this	direction.	Process	Analytical	Technology,	which	is	assessed	in
that	regard,	is	part	of	a	design	quality	approach	that	is	used	to	design,	analyze,	and	control
real‐time	measurements	of	quality	and	performance	criteria	for	raw	and	processed	materials
to	 achieve	 the	 desired	 final	 product.	 This	 scientific	 and	 systematic	 approach	 to
pharmaceutical	 product	 development,	 which	 is	 also	 acknowledged	 and	 supported	 by	 the
health	authorities,	serves	to	the	changing	and	developing	pharmaceutical	sector.	
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1.	Introduction	
	
The	 struggle	 of	 human	 beings	 while	 suffering	 from	
diseases,	 is	a	 journey	going	on	day	by	day	from	the	existence	
and	 will	 continue	 as	 long	 as	 we	 exist.	 During	 this	 process,	
Doctors	and	Pharmacists	are	members	of	a	professional	group	
as	old	as	human	history,	have	used	many	different	medicines	
based	 on	 plants,	 animals	 or	 minerals	 to	 be	 used	 in	 the	
treatment	of	diseases.	The	changing	and	developing	world	has	
brought	 evolution	 and	 globalization	 in	 the	 pharmaceutical	
sector.	However,	 the	 only	 thing	did	not	 change	 is	 the	 impor‐
tance	 of	 the	 drug	 quality.	 The	 pharmaceutical	 industry	 is	 a	
vital	 industry	where	product	quality	is	vital	and	the	ability	to	
produce	 products	 constantly	 at	 the	 desired	 quality	 is	
indispensable	[1].	
The	 increasing	 world	 population	 causes	 changes	 on	 the	
welfare	 level	of	the	societies,	demographics,	and	 living	condi‐
tions,	 consequently	 the	ecological	 equilibrium	 is	affected.	For	
this	 reason,	health	problems	of	people	are	 also	 increasing.	 In	
this	context,	the	quality	of	human	life	is	directly	parallel	to	the	
ability	 to	 produce	 the	medicine	 in	 desired	 quality.	 Thus,	 the	
global	 pharmaceutical	 sector	 is	 constantly	 improving	 and	
investments	 in	research	and	development	(R&D)	and	 innova‐
tion	 are	 increasing.	 The	pharmaceutical	 industry	 is	 a	 lengthy	
and	 costly	 process	 involving	 clinical	 research	 where	 basic	
research	 and	 subsequent	 clinical	 tests	 are	 carried	 out,	 inclu‐
ding	the	 identification	of	effective	molecules,	 the	discovery	of	
new	areas	of	use	for	existing	molecules,	and	the	reassessment	
of	a	side	effect	for	the	drug	under	investigation	[2].	Today,	the	
development	 of	 new	 technologies	 to	 support	 R&D	 and	
production	 processes	 has	 brought	 along	 the	 development	 of	
quality	 medicines	 and	 new	 approaches	 in	 therapy.	 In	 parti‐
cular,	 the	 computer‐assisted	 experimental	 design	 is	 expected	
to	 reduce	 costs	 and	 increase	 quality	 in	 clinical	 research	 and	
manufacturing	processes	[2].	
The	 American	 Food	 and	 Drug	 Administration	 (FDA)	 and	
the	European	Medicines	Agency	(EMA)	make	the	definition	of	
“Quality	 By	 Design”	 as	 a	 scientific,	 systematic,	 and	 risk‐
oriented	 approach	 to	 the	 production	 of	 pharmaceutical	
products	 from	 the	 empirical	 traditional	 processes	 [3].	 This	
approach	 involves	 building	 the	 product	 by	 designing	 the	
stages	of	quality	improvement,	starting	from	the	development	
of	 the	 pharmaceutical	 product.	 In	 addition,	 risks	 in	 the	
production	phase	are	controlled	by	quality	 risk	management.	
Guidelines	such	as	ICH	Q8,	ICH	Q9,	ICH	Q10,	ICH	Q11	and	ICH	
Q12	 published	 by	 the	 International	 Harmonization	 Commis‐
sion	 (ICH)	 detail	 the	 scientific	 and	 innovative	 design	 and	
quality	 perception	 required	 to	 ensuring	 consistent	 product	
quality	[3].	
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Figure	1.	Flow	diagram	for	Quality	by	Design.
	
	
When	 the	 literature	 is	 examined,	 while	 there	 are	 a	 large	
number	of	studies	[4‐12]	in	which	QbD	and	Process	Analytical	
Technology	(PAT)	applications	are	analyzed,	it	is	obvious	that	
conducting	 more	 research	 in	 this	 area	 is	 necessary	 as	 the	
benefits	of	the	field	are	taken	into	consideration.	The	approach	
of	designing	pharmaceutical	products	with	quality	rather	than	
testing	 the	 final	 product	 during	 the	 pharmaceutical	 product	
development	 process,	which	 is	 difficult	 and	 costly,	 is	 a	 topic	
that	attracts	growing	interest.	In	this	sense,	the	applications	of	
the	 QbD	 and	 PAT	 in	 the	 pharmaceutical	 industry	 have	 been	
increasing.	 In	 this	 context,	 this	 study	 will	 present	 the	
advantages	 and	 disadvantages	 provided	 by	 PAT,	 PAT	 steps,	
PAT	tools	and	PAT,	by	putting	emphasis	on	the	necessity	of	the	
QbD	approach.	Subsequently,	the	examples	of	the	applications	
of	PAT	in	the	pharmaceutical	industry	will	be	summarized.	
	
1.1.	Quality	by	design	steps	
	
As	 shown	 in	Figure	1,	 the	 first	 step	 in	design	and	quality	
approach	is	to	determine	the	intended	use	of	the	product	and	
the	appropriate	quality	addressing	this	purpose.	In	the	second	
step,	 the	 scientific	 data	 and	 information	 necessary	 to	 define	
the	 critical	 quality	 characteristics	 are	 evaluated.	 In	 the	 next	
stage,	process	development	is	evaluated	with	concepts	such	as	
experimental	 design,	 process	 analytical	 technology	 and	 risk	
control.	In	addition,	a	design	area	ensuring	quality	in	this	step	
is	 established.	 The	 following	 step	 is	 the	 identification	 and	
design	 of	 the	 control	 strategy.	 In	 the	 last	 step,	 continuous	
improvement	and	life	cycle	are	provided	by	the	combination	of	
quality	risk	management	and	product	process	knowledge.	
In	 the	 traditional	 pharmaceutical	 development	 process,	
univariate	 experiments	 are	 reproducibility	 centered,	 while	
systematic	experiments	that	are	highly	variable	in	design	and	
quality	 are	 conducted	 in	 a	 design	 area	 and	 centered	 on	 the	
control	 strategy.	 However,	 in	 the	 traditional	 approach,	 the	
control	 strategy	 is	 predominantly	 composed	 of	 intermediate	
and	finished	product	tests,	whereas	in	the	design	approach	the	
controls	 are	 made	 in	 the	 production	 phase	 and	 real‐time	
release	 is	 the	case.	Additionally,	process	 control	 is	done	with	
an	 off‐line	 analysis	 in	 the	 traditional	 approach	 while	 PAT	 is	
used	in	design	and	quality	understanding	[1].	
	
1.2.	Proses	analytical	technology	
	
The	 FDA	 (2004)	 defines	 process	 analytical	 technology	 as	
designing,	 analyzing	 and	 controlling	 the	 critical	 quality	
performance	characteristics	of	the	materials	and	processes	in	
the	process	with	real‐time	measurements	to	ensure	the	quality	
of	 the	 final	 product.	 The	 analytical	 term	 in	 this	 approach	 is	
generally	 referring	 to	 an	 integrated	 use	 with	 chemical,	
physical,	microbiological,	mathematical	and	risk	analysis.	
PAT’s	 aim	 is	 to	 understand	 and	 control	 the	 production	
process	 that	 is	 consistent	 with	 our	 current	 drug	 quality	
system.	 In	 this	 respect,	 the	 quality	 concept	 for	 the	
pharmaceutical	 industry	 should	 be	 “The	 quality	 should	 be	
designed	for	pharmaceutical	products	and	the	products	should	
be	built	 in	 this	direction,	 the	quality	 tests	applied	to	 the	 final	
product	do	not	show	the	actual	quality”	[13].	
	
1.2.1.	Proses	analytical	technology	steps	
	
PAT	 consists	 of	 three	 main	 steps	 in	 the	 form	 of	 the	
interrelated	design,	 analysis	 and	 control	 (Figure	2).	 In	deter‐
mining	the	quality	of	the	final	product	at	the	design	step,	it	 is	
necessary	to	determine	the	level	of	effects	of	each	process	step	
and	 starting	material.	 In	 the	 analysis	 step,	 direct	 or	 indirect	
analytical	 tools	are	used	in	real	time	to	determine	the	quality	
features	of	the	process	materials	and	raw	material.	Finally,	 in	
the	 last	 step,	 the	 harmony	 between	 all	 the	 results	 obtained	
through	a	process	control	is	evaluated	[14].	
	
	
	
Figure	2.	Process	analytical	technology	steps.	
	
1.2.2.	Proses	analytical	technology	tools	
	
PAT	tools	include	highly	variable	data	acquisition,	process	
analyzers,	process	control	tools,	and	continuous	improvement	
and	 information	 management	 tools	 for	 data	 collection	 and	
analysis.	 Raman	 Spectroscopy	 (RAMAN),	 Near	 Infrared	
Spectroscopy	 (NIRS),	 Ultraviolet‐Visible	 Region	 Spectroscopy	
(UV‐VIS)	 and	 Nuclear	 Magnetic	 Resonance	 Spectroscopy	
(NMR)	 are	 frequently	 used	 in	 PAT	 applications	 in	 the	
pharmaceutical	 industry.	 Particularly	 NIRS	 is	 widely	 used	 in	
the	determination	of	process	parameters	and	limit	compliance,	
optimum	 values,	 and	 process	 termination	 points,	 in	 many	
units	 such	 as	mixing,	 granulation,	 drying	 and	 coating	 during	
the	production	of	the	solid	oral	dosage	forms.		
On	the	other	hand,	on‐line	chromatographic	methods	and	
viscosity	 measurements	 are	 other	 important	 analytical	 tools	
used	 in	 the	 process	 development.	 In	 assessing	 the	 perfor‐
mance	 of	 the	 production	 process,	 chemometric	 methods,	 a	
useful	 tool	 for	 defining	 mathematical	 correlation,	 can	 be	
applied	 to	 real‐time	 monitoring	 and	 control	 to	 realize	 the	
characterization	of	raw	and	intermediate	products	[1,14,15].	
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Table	1.	Process	analytical	technology	applications	a.	
Application	 PAT	tool	 Statistical	
chemometric	method
Result	 Reference	
Wurster	coating	process	 NIRS	 PLS Can	be	used	for	monitoring	the	Wurster	coating	process		
	
[16]
To	compare	quality	of	
pharmaceutical	excipient	
Raman	
spectroscopy	b	
PCA	 The	proposed	approach	can	form	the	basis		
for	a	risk	reduction	management	system		
	
[17]	
To	optimize	a	tablet	formulation	 NIRS	
Raman	
spectroscopy	
PCA Tablet	formulation	can	be	designed	by	using	QbD		
	
[18]
To	determine	the	quantification	of	
active	pharmaceutical	ingredients	
using	PAT	
Fluorescence	
spectroscopy	
PLS Rapid	and	non‐destructive	method	was	developed	
simultaneous	quantification	of	two	active	pharmaceutical	
ingredients	in	a	tablet	formulation	
[19]
To	develop	a	new	method	using	
direct	analysis	in	real	time	mass	
spectrometry	with	PAT	
DART‐MS	
HPLC	
Not	required Rapid	process	development	method	was	proposed	using	
PAT		
[20]
To	investigate	on	line	quantitative	
monitoring	of	alcohol	precipitation	
NIRS	 PSO,	LS‐SVM,	PLS	 Can	be	used	as	a	process	analyzer	for		
noninvasive	and	online	quantitative	monitoring	of	alcohol	
precipitation	
[21]	
To	investigate	crystallization	process	 UV	Vis	c	 PCA PAT	tools	can	be	used	to	explore	crystallization	process	 [22]
To	evaluate	and	control	the	coating	
process	of	drug	
NIRS	
	
PLS PAT	can	be	used	for	drug	coating	process		
	
[23]
Pharmaceutical	granulation	process NIRS	 PLS NIRS	is	a	useful	PAT	tool [24]
	
Extraction	process	 NIRS	 PLS	 Successful	models	have	been	built	and	applied		
online	for	extraction	process	
[25]	
a	Abbreviations:	NIRS:	Near‐Infrared	Spectroscopy,	PLS:	Partial	Least	Squares,	PCA:	Principal	Component	Analysis,	QbD:	Quality	by	Design,	DART‐MS:	Direct	
Analysis	in	Real	Time	Mass	Spectrometry,	HPLC:	High	Performance	Liquid	Chromatography,	PSO:	Particle	Swarm	Optimization	LS‐SVM:	Least	Square	Support	
Vector	Machines.	
b	Also,	laser	diffraction	and	X‐ray	powder	diffraction	methods	were	used.	
c	Ultra	Violet/Visible	spectroscopy,	focused	beam	reflectance	measurement	(FBRM)	and	the	CryPRINS	software	(Crystallization	Process	Informatics	System).	
	
1.2.3.	Advantages	and	disadvantages	of	proses	analytical	
technology	applications	
	
Perhaps	the	most	important	benefit	of	using	the	PAT	to	the	
pharmaceutical	industry	is	that	it	can	be	intervened	while	the	
processes	are	going	on.	 In	other	words,	errors	can	be	correc‐
ted	while	the	process	is	in	progress,	so	that	material	losses	can	
be	 avoided.	 At	 the	 same	 time,	 since	 the	 real‐time	 control	
strategy	 is	 concerned,	 the	 production	 efficiency	 can	 be	
achieved	 without	 sacrificing	 quality.	 In	 this	 respect,	 quality	
and	 stable	 products	 can	 be	 produced	 in	 a	 shorter	 period	 of	
time,	 in	 the	context	of	better	process	control,	providing	 long‐
term	economic	benefits.	
One	 of	 the	major	 problems	 encountered	with	 PAT	 is	 the	
adaptation	problem	during	the	integration	of	the	applications	
based	 on	 quality	 and	 design	 and	 PAT	 approach	 into	 the	
existing	system.	It	is	clear	that	revision	of	the	traditional	phar‐
maceutical	 product	 development	 process	 already	 in	 place	
needs	 a	 major	 role	 played	 by	 official	 authorities,	 applicants,	
and	 sectorial	 employees.	 This	 is	 because	 there	 is	 a	 need	 for	
training	 and	 working	 devotedly	 at	 every	 step	 to	 build	 this	
understanding	 based	 on	 quality	 building	 and	 to	 revise	 the	
existing	 traditional	 approach.	 Moreover,	 it	 is	 necessary	 to	
develop	 measurement	 tools	 and	 data	 analysis	 methods	 in	
order	 to	 better	 understand	 the	 chemical	 and	 pharmaceutical	
processes	and	to	understand	their	contribution	to	quality.	
	
2.	Applications	of	proses	analytical	technology	in	drug	
industry	as	part	of	quality	by	design	
	
PAT	 is	 used	 in	 different	 fields	 of	 the	 pharmaceutical	
industry	 such	 as	 extraction	 and	 crystallization	 processes,	
production	 of	 solid	 dosage	 forms,	 tablet	 pressing,	 quantify‐
cation	 of	 active	 and	 auxiliary	 substances,	 blending,	 granula‐
tion,	and	coating	processes.	In	this	context,	examples	of	differ‐
rent	PAT	applications	used	in	the	pharmaceutical	industry	are	
given	in	Table	1.	
Naidu	et	al.	[16]	aimed	improving	understanding	of	multi‐
particulate	drug	delivery	system	by	monitoring	percent	weight	
build‐up	during	the	functional	coating	process	of	drug‐loaded	
pellets	 within	 QbD	 framework.	 An	 at‐line	 NIR	 spectroscopy	
was	 used	 as	 PAT	 tool.	 The	 authors	 reported	 that	 they	 deve‐
loped	an	at‐line	NIR	spectroscopy	method	for	monitoring	the	
progress	of	Wurster	coating	operation	without	contacting	and	
destructing	the	sample.	
Hertrampf	et	al.	[17]	compared	the	quality	of	pharmaceu‐
tical	 excipients,	 manufactured	 on	 three	 different	 production	
lines.	They	aimed	 to	 identify	which	continuous	process	ensu‐
res	 a	 similar	 product	 quality	 to	 that	 of	 batch	processing.	 For	
this	purpose,	different	analytical	methods	were	used.	Authors	
reported	that	the	proposed	approach	can	form	the	basis	for	a	
risk	 reduction	 and	 management	 system	 with	 regard	 to	
sourcing	and	manufacturability.	
Chavez	et	al.	 [18]	 studied	 to	optimize	 the	 tablet	 formula‐
tion	using	QbD	approach.	For	this	purpose,	Fourier	Transform	
Infrared	 and	 Raman	 spectroscopy	 instruments	were	 used	 as	
PAT	tools.	The	authors	analyzed	the	data	by	principal	compo‐
nent	analysis.	
Warnecke	et	al.	[19]	aimed	to	determine	the	quantification	
of	 active	 pharmaceutical	 ingredients	 using	 process	 analytical	
technology.	The	samples	were	analyzed	by	Fluorescence	spect‐
roscopy	 and	 the	 data	 analysis	was	performed	using	 a	 partial	
least	 squares	 regression.	 In	 addition,	 the	 goal	 of	 the	 study	
conducted	by	Yan	et	al.	[20]	was	set	to	develop	a	new	method	
using	direct	analysis	in	real	time	mass	spectrometry	as	a	PAT	
tool.	Based	on	this	PAT	tool,	the	impacts	of	process	parameters	
on	 the	 adsorption	 capacity	 were	 discovered	 rapidly.	 The	
authors	reported	that	the	proposed	approach	was	model	free	
and	did	not	require	use	of	any	calibration	model.	
Jin	et	al.	[21]	aimed	to	use	NIR	spectroscopy	for	online	and	
real	time	quantitative	monitoring	of	alcohol	precipitation.	The	
developed	 NIR	 models	 were	 successfully	 applied	 for	 quanti‐
tative	 analysis	 of	 the	 critical	 intermediate	 quality	 attributes	
during	alcohol	precipitation.	Simone	et	al.	 [22]	designed	their	
study	to	illustrate	how	an	array	PAT	tool	could	be	used	at	the	
crystallization	 process	 of	 a	 biopharmaceutical	 compound	 in	
the	 presence	 of	 impurities.	 The	 authors	 used	 different	 PAT	
tools	to	learn	crystallization	process	of	the	biopharmaceutical	
compound.	
Kim	et	al.	[23]	purposed	to	develop	a	validated	NIRS	met‐
hod	for	evaluating	and	controlling	the	tablet	coating	process	of	
a	drug	with	low	therapeutic	dose,	Glimepiride.	
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Rosas	et	al.	[24]	developed	a	method	for	the	non‐invasive	
determination	 of	 the	 critical	 quality	 attributes	 (CQAs)	 of	 a	
pharmaceutical	 granulate	with	 a	 view	 to	 reduce	 its	manufac‐
turing	time	and	to	obtain	a	better	knowledge	of	the	effects	of	
some	variables	used	in	the	production	process.	They	reported	
that	near	 Infrared	 spectroscopy	 (NIRS)	has	been	successfully	
used	to	develop	faster	and	non‐invasive	quantitative	methods	
for	real‐time	prediction	of	the	critical	quality	attributes	(CQA)	
of	 pharmaceutical	 granulates	 (API	 content,	 pH,	 moisture,	
flowability,	the	angle	of	repose,	and	particle	size).	
Wu	et	al.	[25]	considered	the	feasibility	of	using	NIR	spect‐
roscopy	as	a	process	analyzer	for	the	non‐invasive,	online	and	
real‐time	 monitoring	 of	 extraction	 process	 for	 traditional	
Chinese	medicine.	
	
3.	Conclusion		
	
The	 quality	 by	 design	 for	 pharmaceutical	 products	 and	
processes	is	a	systematic,	scientific	and	risk‐based	approach	to	
the	development	of	every	step	involving	in	the	pharmaceutical	
manufacturing	 in	 the	 direction	 of	 pre‐determined	 goals.	 This	
approach	controls	 the	quality	assurance	of	the	drug,	which	 is	
the	 biggest	 output	 of	 the	 pharmaceutical	 industry	 that	 has	
human	health	in	the	center.	The	process	analytical	technology	
that	 the	 design	 and	 the	 quality	 used	 together	with	 analytical	
tools	is	a	powerful	quality	by	design	used	for	designing,	const‐
ructing,	and	controlling	the	quality	of	the	product.	It	is	known	
that	the	number	of	process	analytical	technology	applications	
in	 the	 pharmaceutical	 industry	 are	 increasingly	 growing	 and	
hence,	the	number	of	license	applications	used	this	approach	is	
rising	 rapidly.	 The	 understanding	 and	 implementing	 design	
and	quality	as	well	as	process	analytical	 technology	practices	
increase	 the	quality	of	pharmaceutical	products,	reduce	costs	
over	 the	 long	 term,	 and	 modernize	 the	 supervision	 of	 the	
pharmaceutical	 industry.	 The	 continuity	 of	 drug	 quality	 is	
indispensable	 for	 manufacturers,	 supervisory	 agencies	 and	
patients,	which	makes	these	studies	one	of	the	priorities	in	the	
field	and,	requires	further	research.	
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